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Purpose/Objective: High dose image guided radiotherapy (IGRT) using 
prostate fiducials is standard of care for low and intermediate risk 
patients. However, high risk patients also benefit from prophylactic 
intensity modulated radiotherapy (IMRT) to the lymph nodes. The 
prostate can move independently to the pelvic nodes, therefore the 
safety of combining fiducial IGRT and pelvic nodal IMRT in high risk 
patients is uncertain. We aim to ascertain the dosimetric impact of 
employing fiducial-based hybrid IG-IMRT on the lymph node planning 
target volume (PTV).  
Materials and Methods: Thirty consecutive IMRT prostate and pelvic 
lymph node dosimetric plans were retrospectively reviewed after 
recalculation with incremental 1mm isocentre movements in all 
directions up to 10mm. In our centre, all IGRT images and shifts are 
recorded creating a population based database. Combining this 
database and the dosimetric data we calculated the overall risk of 
failing to maintain the following lymph node PTV statistics with 
fiducial IG-IMRT:  
- PTV receiving > 99% of target dose (V99%) > 90%,  
- PTV receiving > 95% of target dose (V95%) > 95%  
- PTV receiving > 50% of target dose (V50%) > 100%. 
Results: Shifts in the left, right, and anterior directions do not have a 
significant impact on dose delivery with less than 0.25% risk of PTV 
coverage failure. Shifts posteriorly have the largest impact on dose 
but this still has less than 1% risk of failing PTV coverage.  
Conclusions: The risk of failing lymph node PTV coverage is very low 
with IG-IMRT and therefore we recommend adopting IG-IMRT in high 
risk prostate cancer patients receiving prophylactic lymph node 
irradiation. This will allow a reduction in CTV to PTV margins to the 
prostate volume leading to reduced toxicity and scope for dose 
escalation. 
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Purpose/Objective: Technological advanced in stereotactic body 
radiation therapy have allowed precise targeting and delivery of 
radiation to the prostate while sparing normal tissues. This is suitable 
device for performing hypofractionated stereotactic body 
radiotherapy. We report our experience using cyberknife to patients 
with localized prostate cancer.  
Materials and Methods: This study was based on a retrospective 
analysis of the 65 patients treated with CyberKnife radiotherapy for 
localized prostate cancer. Image-guided SBRT was delivered to all 
patients using the CyberKnife (Accuray Inc., Sunnyvale, CA) with 
motion tracking of internal fiducial seeds. Thirty-five patients 
identified as low and favorable intermediate risk group received 
irradiation at a dose of 36.25 Gy in 5 fractions of 7.25 Gy per fraction. 
Thirty-two unfavorable intermediate and high risk group patients 
received 45 Gy at whole pelvis by three dimensional radiation therapy 
or intensity modulated radiation therapy and received a boost by the 
CyberKnife at dose of 21 Gy in 3 fractions. The acute and late 
toxicities were recorded using the Radiation Therapy Oncology Group 
scale and the CTCAE, version 4.0. Prostate-specific antigen response 
was monitored. 
Results: All 65 patients finished planed radiation therapy without any 
severe complication. The median follow-up for patients was 36 
months (range 6 - 56 months). There were two biochemical failures in 
high risk patient who received whole pelvis radiation therapy and 
cyberknife boost. Acute Grade 1 and Grade 2 gastrointestinal (GI) 
toxicities were observed in 38.5% and 3.1% of the patients, 
respectively. There were no acute Grade 3 or 4 GI toxicities. Late 
Grade 3 GI toxicity, rectal bleeding, was noted in 2 patient in high risk 
group (3.1%) but bleeding was stopped with 3 times laser coagulation 
in one patients. Acute Grade 1 and Grade 2 genitourinary (GU) 
toxicities were seen in 43.1% and 21.5%of the patients, respectively. 
There was acute Grade 3 urinary frequency in one patients of high risk 
group.  
Conclusions: Our results showed favorable biochemical response and 
low toxicity for hypofractionated stereotactic body radiotherapy with 
CyberKnife for localized prostate cancer. However, more follow up 
with a larger cohort is required to confirm durable biochemical 
control rates and late toxicity profiles.  
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Purpose/Objective: To determine the optimal planning target volume 
(PTV) margins in image-guided radiotherapy (IGRT) for prostate 
cancer, intra-fraction prostate motion was examined. 
Materials and Methods: During 32 fractions of Cyberknife treatment, 
prostate motion as tracked by the stereoscopic X-ray images of the 
implanted fiducials was examined. The CyberKnife uses a stereoscopic 
X-ray system to obtain the position of the prostate target through the 
monitoring of implanted fiducial markers. If there is a significant 
deviation, the treatment is paused while the patient is repositioned 
by moving the couch. The deviations calculated from X-ray images 
acquired within the time interval between two consecutive couch 
motions constitute a data set. 
Results: The averages of intra-fractional motion of fiducial markers 
were 1.1 mm for cranio-caudal, 0.3 mm for left-right, and 1.2 mm for 
antero-posterior. The maximum of intra-fractional motion of fiducial 
markers were 7.9 mm for cranio-caudal, 2.1 mm for left-right, and 
11.5 mm for antero-posterior. Intra-fractional fiducial marker motion 
of 5.0 mm or greater was observed only in two fractions among 32 
fractions. In addition, incidence of intra-fractional fiducial marker 
motion of 3.0 mm or greater increased with time in cranio-caudal and 
antero-posterior. 
Conclusions: Although PTV margins of 10 mm or greater is necessary 
to completely cover the intra-fractional prostate motion, PTV margins 
of 5 mm were adequate to cover the cranio-caudal and antero-
posterior intra-fractional prostate motion in more than 90% of 
fractions. PTV margins of left-right seemed to be able to reduce to 3 
mm. Reduction of treatment time is needed to reduce the PTV 
margins in IGRT of prostate cancer. 
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Purpose/Objective: To investigate the spatial and temporal 
variability of the endorectal balloon (ERB) position in the setting of 
postoperative radiotherapy and to investigate the impact of ERB 
variability on the dose delivered to the rectal wall (Rwall). 
Materials and Methods: For 7 patients with biochemical recurrence 
after prostatectomy and referred for salvage radiotherapy of the 
prostate bed, a daily-inserted air-filled (50ml) ERB was applied and a 
VMAT planning technique was used. The prescription dose was 66Gy 
(2Gy/fraction). During treatment, weekly control CTs were acquired 
and translational matches to the reference CT by means of 
surrounding pelvic bones (symphysis etc.) were performed. Rectum, 
rectum balloon and rectal wall structures were contoured and the 
original treatment plan was calculated on the control CT. The relative 
volumes of Rwall exposed to doses ≥ 40Gy (V40), ≥ 60Gy(V60), ≥ 
65Gy(V65) were calculated. Additionally, the balloon shifts (changes in 
distance from the rectum balloon center to the isocenter) were 
measured. The dose volumes and balloon shifts were plotted against 
the time (number of days between the respective control CT and the 
planning CT). Significance tests were made for each patient for 
detecting systematic changes over treatment time. 
Results: The figure shows a graph of the balloon shifts for each 
patient over time. R2 statistics and p values were calculated to check 
if the observed trend that the balloon shifts away from the isocenter 
over time was significant. Significance was found only in one patient. 
